Your browser is no longer supported. Please, upgrade your browser.
AERI Aerie Pharmaceuticals, Inc. daily Stock Chart
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.42 Insider Own1.60% Shs Outstand45.88M Perf Week-14.86%
Market Cap450.31M Forward P/E- EPS next Y-2.33 Insider Trans-0.68% Shs Float45.52M Perf Month-14.86%
Income-201.80M PEG- EPS next Q-0.80 Inst Own- Short Float19.24% Perf Quarter-19.89%
Sales81.60M P/S5.52 EPS this Y21.30% Inst Trans0.80% Short Ratio11.97 Perf Half Y-32.77%
Book/sh1.96 P/B5.06 EPS next Y27.50% ROA-46.70% Target Price- Perf Year-52.34%
Cash/sh5.32 P/C1.86 EPS next 5Y- ROE-136.10% 52W Range9.01 - 26.26 Perf YTD-59.00%
Dividend- P/FCF- EPS past 5Y-17.10% ROI-52.70% 52W High-62.26% Beta0.64
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin79.00% 52W Low9.99% ATR0.68
Employees380 Current Ratio3.70 Sales Q/Q13.90% Oper. Margin- RSI (14)38.21 Volatility9.16% 5.86%
OptionableYes Debt/Eq2.22 EPS Q/Q-1.10% Profit Margin- Rel Volume1.43 Prev Close9.68
ShortableYes LT Debt/Eq2.22 EarningsAug 06 AMC Payout- Avg Volume731.87K Price9.91
Recom1.80 SMA20-11.83% SMA50-13.40% SMA200-32.71% Volume1,044,805 Change2.38%
Oct-19-20Downgrade BofA Securities Neutral → Underperform $14 → $9
Sep-08-20Resumed Guggenheim Buy $20
Aug-07-20Reiterated Needham Buy $32 → $26
Jun-01-20Resumed Oppenheimer Outperform $22 → $24
May-07-20Reiterated H.C. Wainwright Buy $37 → $31
Jan-10-20Initiated BofA/Merrill Neutral $27
Jan-09-20Initiated SunTrust Buy $32
Dec-19-19Initiated Citigroup Buy $36
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Oct-20-20 06:28AM  
Oct-15-20 09:20AM  
Oct-14-20 12:30AM  
Oct-05-20 12:01PM  
Sep-30-20 09:10AM  
Sep-29-20 06:30AM  
Sep-24-20 06:30AM  
Sep-18-20 09:00AM  
Sep-15-20 06:45AM  
Sep-09-20 07:45AM  
Sep-08-20 07:30AM  
Sep-05-20 11:31AM  
Aug-21-20 09:01AM  
Aug-10-20 10:01AM  
Aug-07-20 10:53AM  
Aug-06-20 04:01PM  
Jul-30-20 07:30AM  
Jul-29-20 12:33PM  
Jul-27-20 06:30AM  
Jul-17-20 02:06PM  
Jul-02-20 08:11AM  
Jun-15-20 06:04PM  
Jun-11-20 06:30AM  
Jun-05-20 11:31AM  
Jun-03-20 03:40AM  
May-11-20 07:15PM  
May-07-20 06:30PM  
May-06-20 05:15PM  
May-05-20 07:30AM  
Apr-29-20 07:30AM  
Apr-28-20 12:34PM  
Apr-13-20 10:01AM  
Apr-09-20 04:01PM  
Apr-07-20 07:30AM  
Apr-02-20 02:54PM  
Mar-25-20 10:18AM  
Mar-21-20 11:30AM  
Feb-27-20 07:23AM  
Feb-24-20 02:59PM  
Feb-21-20 11:30AM  
Feb-20-20 05:35PM  
Feb-18-20 06:30AM  
Feb-13-20 07:30AM  
Feb-12-20 05:13AM  
Feb-03-20 06:30AM  
Jan-21-20 06:30AM  
Jan-08-20 05:18PM  
Jan-07-20 05:26AM  
Jan-03-20 10:04AM  
Jan-02-20 08:46AM  
Dec-09-19 06:30AM  
Dec-06-19 11:31AM  
Dec-04-19 09:19AM  
Dec-03-19 06:15AM  
Dec-02-19 04:56AM  
Nov-27-19 09:45AM  
Nov-26-19 06:30AM  
Nov-22-19 08:18AM  
Nov-21-19 06:30AM  
Nov-19-19 10:58AM  
Nov-18-19 06:30AM  
Nov-12-19 07:30AM  
Nov-07-19 10:51AM  
Nov-06-19 06:05PM  
Nov-05-19 06:30AM  
Oct-30-19 07:30AM  
Oct-29-19 10:33AM  
Oct-28-19 06:13PM  
Oct-25-19 06:40AM  
Oct-24-19 06:30AM  
Oct-16-19 07:15PM  
Oct-07-19 06:30AM  
Sep-25-19 07:30AM  
Sep-23-19 01:20PM  
Sep-20-19 06:30AM  
Sep-19-19 07:39AM  
Sep-16-19 11:46AM  
Sep-10-19 09:36PM  
Sep-09-19 07:15PM  
Sep-06-19 02:42PM  
Sep-05-19 08:12AM  
Sep-04-19 08:20PM  
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDBERG MURRAY ADirectorMay 18Option Exercise3.1528,00088,20036,050May 20 06:45 PM
Cagle Gerald D.DirectorMay 08Sale15.275,00076,35016,550May 12 05:25 PM
Foresite Capital Management II10% OwnerFeb 27Sale17.071,000,00017,070,0001,229,633Mar 02 05:01 PM
Kopczynski Casey C.Chief Scientific OfficerDec 03Option Exercise0.41117,00047,385218,511Dec 05 04:06 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.